{
  "id": 16330940,
  "title": "Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer",
  "url": "https://urgent.news/2026/10/24/genmab-incyte-partner-on-trial-of-petosemtamab-combination-in-kras",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-24T12:27:06.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/genmab-incyte-partner-trial-petosemtamab-combination-kras-g12d-mutated-colorectal-cancer"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Genmab A/S (GMAB) and Incyte (INCY) have entered into a clinical trial collaboration to evaluate a novel combination therapy for patients with metastatic colorectal cancer (mCRC) harboring a KRAS G12D mutation, a population with significant unmet medical needs.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}